Compare VAL & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VAL | LGND |
|---|---|---|
| Founded | 1975 | 1987 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.9B |
| IPO Year | N/A | 1992 |
| Metric | VAL | LGND |
|---|---|---|
| Price | $58.69 | $195.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $54.80 | ★ $243.50 |
| AVG Volume (30 Days) | ★ 1.0M | 236.1K |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.76 |
| EPS | ★ 5.61 | 2.49 |
| Revenue | ★ $2,416,000,000.00 | $251,233,000.00 |
| Revenue This Year | N/A | $47.71 |
| Revenue Next Year | N/A | $9.77 |
| P/E Ratio | ★ $10.14 | $76.38 |
| Revenue Growth | 6.81 | ★ 64.83 |
| 52 Week Low | $27.15 | $93.58 |
| 52 Week High | $61.70 | $212.49 |
| Indicator | VAL | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 66.24 | 48.63 |
| Support Level | $55.95 | $188.13 |
| Resistance Level | $59.54 | $207.06 |
| Average True Range (ATR) | 2.03 | 8.48 |
| MACD | 0.61 | -0.60 |
| Stochastic Oscillator | 80.00 | 55.25 |
Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.